India, Nov. 16 -- British drug major AstraZeneca PLC (AZN,AZN.L) announced Monday that Klygefa (gefurulimab), from Alexion, AstraZeneca Rare Disease, has been approved in the European Union for the treatment of adults with generalised myasthenia gravis or gMG, a rare autoimmune disorder.
The drug has received EU approval as an add-on to standard therapy for the treatment of gMG in adults who are anti-acetylcholine receptor (AChR) antibody positive
According to the firm, Klygefa is the first and only dual-binding nanobody C5 inhibitor in the region, offering once-weekly subcutaneous self-administration via autoinjector with rapid and sustained disease control.
The EU approval follows the positive opinion of the Committee for Medicinal Pro...